Pierce into Structural Changes of Interactions Between Mutated Spike Glycoproteins and ACE2 to Evaluate Its Potential Biological and Therapeutic Consequences
Abstract The structural consequences of ongoing mutations on the SARS-CoV-2 spike-protein remains to be fully elucidated. These mutations could change the binding affinity between the virus and its target cell. Moreover, obtaining new mutations would also change the therapeutic efficacy of the designed drug candidates. To evaluate these consequences, 3D structure of a mutant spike protein was predicted and checked for stability, cavity sites, and residue depth. The docking analyses were performed between the 3D model of the mutated spike protein and the ACE2 protein and an engineered therapeutic ACE2 against COVID-19. The obtained results revealed that the N501Y substitution has altered the interaction orientation, augmented the number of interface bonds, and increased the affinity against the ACE2. On the other hand, the P681H mutation contributed to the increased cavity size and relatively higher residue depth. The binding affinity between the engineered therapeutic ACE2 and the mutant spike was significantly higher with a distinguished binding orientation. It could be concluded that the mutant spike protein increased the affinity, preserved the location, changed the orientation, and altered the interface amino acids of its interaction with both the ACE2 and its therapeutic engineered version. The obtained results corroborate the more aggressive nature of mutated SARS-CoV-2 due to their higher binding affinity. Moreover, designed ACe2-baased therapeutics would be still highly effective against covid-19, which could be the result of conserved nature of cellular ACE2..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
International journal of peptide research and therapeutics - 28(2021), 1 vom: 16. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hashemi, Zahra Sadat [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Lineage B.1.1.7. |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. 2021 |
|---|
| doi: |
10.1007/s10989-021-10346-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2077650400 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2077650400 | ||
| 003 | DE-627 | ||
| 005 | 20230511095301.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10989-021-10346-1 |2 doi | |
| 035 | |a (DE-627)OLC2077650400 | ||
| 035 | |a (DE-He213)s10989-021-10346-1-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.76$jAminosäuren$jPeptide$jEiweiße$XBiochemie |2 bkl | ||
| 100 | 1 | |a Hashemi, Zahra Sadat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pierce into Structural Changes of Interactions Between Mutated Spike Glycoproteins and ACE2 to Evaluate Its Potential Biological and Therapeutic Consequences |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. 2021 | ||
| 520 | |a Abstract The structural consequences of ongoing mutations on the SARS-CoV-2 spike-protein remains to be fully elucidated. These mutations could change the binding affinity between the virus and its target cell. Moreover, obtaining new mutations would also change the therapeutic efficacy of the designed drug candidates. To evaluate these consequences, 3D structure of a mutant spike protein was predicted and checked for stability, cavity sites, and residue depth. The docking analyses were performed between the 3D model of the mutated spike protein and the ACE2 protein and an engineered therapeutic ACE2 against COVID-19. The obtained results revealed that the N501Y substitution has altered the interaction orientation, augmented the number of interface bonds, and increased the affinity against the ACE2. On the other hand, the P681H mutation contributed to the increased cavity size and relatively higher residue depth. The binding affinity between the engineered therapeutic ACE2 and the mutant spike was significantly higher with a distinguished binding orientation. It could be concluded that the mutant spike protein increased the affinity, preserved the location, changed the orientation, and altered the interface amino acids of its interaction with both the ACE2 and its therapeutic engineered version. The obtained results corroborate the more aggressive nature of mutated SARS-CoV-2 due to their higher binding affinity. Moreover, designed ACe2-baased therapeutics would be still highly effective against covid-19, which could be the result of conserved nature of cellular ACE2. | ||
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Lineage B.1.1.7. | |
| 650 | 4 | |a Mutation | |
| 650 | 4 | |a Spike protein | |
| 650 | 4 | |a Structural analyses | |
| 700 | 1 | |a Zarei, Mahboubeh |4 aut | |
| 700 | 1 | |a Mubarak, Shaden M. H. |4 aut | |
| 700 | 1 | |a Hessami, Anahita |4 aut | |
| 700 | 1 | |a Mard-Soltani, Maysam |4 aut | |
| 700 | 1 | |a Khalesi, Bahman |4 aut | |
| 700 | 1 | |a Zakeri, Alireza |4 aut | |
| 700 | 1 | |a Rahbar, Mohammad Reza |4 aut | |
| 700 | 1 | |a Jahangiri, Abolfazl |4 aut | |
| 700 | 1 | |a Pourzardosht, Navid |4 aut | |
| 700 | 1 | |a Khalili, Saeed |0 (orcid)0000-0003-0493-9595 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of peptide research and therapeutics |d Springer Netherlands, 2005 |g 28(2021), 1 vom: 16. Dez. |w (DE-627)490328148 |w (DE-600)2193110-0 |x 1573-3149 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2021 |g number:1 |g day:16 |g month:12 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10989-021-10346-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 936 | b | k | |a 35.76$jAminosäuren$jPeptide$jEiweiße$XBiochemie |q VZ |0 181571129 |0 (DE-625)181571129 |
| 951 | |a AR | ||
| 952 | |d 28 |j 2021 |e 1 |b 16 |c 12 | ||